J&J’s Wu On Nurturing Innovation In Asia
Dong Wu, head of J&J Innovation, Asia Pacific, outlines to Scrip the group’s partnering approach in South Korea and the Asia Pacific in general. He also offers some tips to Korean companies that are keen to pursue global partnerships.
You may also be interested in...
Amid ongoing interest in accessing innovative assets, including those from South Korea, big pharma participants at a recent symposium in Seoul shared the ins and outs of the complex partnering process.
South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.